iRadimed

IRMD

Market cap $1.3B

ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) -- iRadimed Corporation (the “Company”) (NASDAQ: IRMD), announced that its Board of Directors (the “Board”) approved a special cash dividend of $0.50 per share of the Company's outstanding common stock. This special cash dividend is payable on December 30, 2025, to stockholders of record at the close of business on December 17, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company produces the only known non-magnetic intravenous (“IV”) infusion pump system and a non-magnetic patient vital signs monitoring system designed for use during MRI procedures.

Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance Recognized for Exceptional Revenue Growth, Financial Stability, and Stock Performance

Iradimed's CEO, President, and Chairman of the Board, Roger Susi, recently sold 5,000 shares on the open market. The transaction represented roughly 1% of his indirect holdings.

IRADIMED CORPORATION ( IRMD ) Q3 2025 Earnings Call November 3, 2025 11:00 AM EST Company Participants Roger Susi - Founder, Chairman, CEO & President John Glenn - CFO & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Kyle Bauser - ROTH Capital Partners, LLC, Research Division Presentation Operator Welcome to the IRADIMED CORPORATION Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, November 3, 2025, and contains time-sensitive accurate information that is valid only for today.

Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance Announces Regular Quarterly Cash Dividend of $0.17 Per Share and Raises Full-Year Guidance

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 third quarter financial results before the market opens on Monday, November 3, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.

iRadimed (IRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ORLANDO, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and infusion systems, today announced that it will participate in the Wells Fargo 2025 Healthcare Conference, held September 3-5, 2025, in Boston, Massachusetts.

IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.

iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.